Abstract
Reducing cell death during the secondary injury is a major priority in the development of a cure for traumatic spinal cord injury (SCI). One of the earliest processes that follow SCI is the excitotoxicity resulting from the massive release of excitotoxicity mediators, including ATP, which induce an excessive and/or prolonged activation of their receptors and a deregulation of the calcium homeostasis. Diadenosine tetraphosphate (Ap4A) is an endogenous purinergic agonist, present in both extracellular and intracellular fluids, with promising cytoprotective effects in different diseases including neurodegenerative processes. In a search for efficient neuroprotective strategies for SCI, we have tested the capability of Ap4A to reduce the excitotoxic death mediated by the ATP-induced deregulation of calcium homeostasis and its consequences on tissue preservation and functional recovery in a mouse model of moderate contusive SCI. Our analyses with the murine neural cell line Neuro2a demonstrate that treatment with Ap4A reduces ATP-dependent excitotoxic death by both lowering the intracellular calcium response and decreasing the expression of specific purinergic receptors. Follow-up analyses in a mouse model of contusive SCI showed that acute administration of Ap4A following SCI reduces tissue damage and improves motor function recovery. These results suggest that Ap4A cytoprotection results from a decrease of the purinergic tone preventing the effects of a massive release of ATP after SCI, probably together with a direct induction of anti-apoptotic and pro-survival pathways via activation of P2Y2 proposed in previous studies. In conclusion, Ap4A may be a good candidate for an SCI therapy, particularly to reduce excitotoxicity in combination with other modulators and/or inhibitors of the excitotoxic process that are being tested.
Similar content being viewed by others
References
Liu XZ, Xu XM, Hu R et al (1997) Neuronal and glial apoptosis after traumatic spinal cord injury. J Neurosci 17:5395–5406
Olney JW (1969) Glutaate-induced retinal degeneration in neonatal mice. Electron microscopy of the acutely evolving lesion J Neuropathol Exp Neurol 28:455–474
Lipton SA, Rosenberg PA (1994) Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med 330:613–622. doi:10.1056/NEJM199403033300907
Ray SK, Hogan EL, Banik NL (2003) Calpain in the pathophysiology of spinal cord injury: neuroprotection with calpain inhibitors. Brain Res Rev 42:169–185. doi:10.1016/S0165-0173(03)00152-8
Casha S, Yu WR, Fehlings MG (2001) Oligodendroglial apoptosis occurs along degenerating axons and is associated with FAS and p75 expression following spinal cord injury in the rat. Neuroscience 103:203–218. doi:10.1016/S0306-4522(00)00538-8
Lu J, Ashwell KW, Waite P (2000) Advances in secondary spinal cord injury: role of apoptosis. Spine (Phila Pa 1976) 25:1859–1866
Demjen D, Klussmann S, Kleber S et al (2004) Neutralization of CD95 ligand promotes regeneration and functional recovery after spinal cord injury. Nat Med 10:389–395. doi:10.1038/nm1007
Tator CH, Fehlings MG (1991) Review of the secondary injury theory of acute spinal cord trauma with emphasis on vascular mechanisms. J Neurosurg 75:15–26. doi:10.3171/jns.1991.75.1.0015
Choi D (1988) Glutamate neurotoxicity and diseases of the nervous system. Neuron 1:623–634. doi:10.1016/0896-6273(88)90162-6
Wang X, Arcuino G, Takano T et al (2004) P2X7 receptor inhibition improves recovery after spinal cord injury. Nat Med 10:821–827. doi:10.1038/nm1082
Neary JT, Rathbone MP, Cattabeni F et al (1996) Trophic actions of extracellular nucleotides and nucleosides on glial and neuronal cells. Trends Neurosci 19:13–18
Abbracchio MP, Burnstock G (1998) Purinergic signalling: pathophysiological roles. Jpn J Pharmacol 78:113–145
Zhang X, Zhang M, Laties AM, Mitchell CH (2005) Stimulation of P2X7 receptors elevates Ca2+ and kills retinal ganglion cells. Invest Ophthalmol Vis Sci 46:2183–2191. doi:10.1167/iovs.05-0052
Hu H, Lu W, Zhang M et al (2010) Stimulation of the P2X7 receptor kills rat retinal ganglion cells in vivo. Exp Eye Res 91:425–432. doi:10.1016/j.exer.2010.06.017
Mitchell CH, Lu W, Hu H et al (2009) The P2X7 receptor in retinal ganglion cells: a neuronal model of pressure-induced damage and protection by a shifting purinergic balance. Purinergic Signal 5:241–249. doi:10.1007/s11302-009-9142-6
Cisneros-Mejorado A, Pérez-Samartín A, Gottlieb M, Matute C (2015) ATP signaling in brain: release, excitotoxicity and potential therapeutic targets. Cell Mol Neurobiol 35:1–6. doi:10.1007/s10571-014-0092-3
Domercq M, Perez-Samartin A, Aparicio D et al (2010) P2X7 receptors mediate ischemic damage to oligodendrocytes. Glia 58:730–740. doi:10.1002/glia.20958
Cho J-H, Choi I-S, Jang I-S (2010) P2X7 receptors enhance glutamate release in hippocampal hilar neurons. Neuroreport 21:865–870. doi:10.1097/WNR.0b013e32833d9142
Gu JG, MacDermott AB (1997) Activation of ATP P2X receptors elicits glutamate release from sensory neuron synapses. Nature 389:749–753. doi:10.1038/39639
Duan S, Anderson CM, Keung EC et al (2003) P2X7 receptor-mediated release of excitatory amino acids from astrocytes. J Neurosci 23:1320–1328
Burnstock G (1978) A basis for distinguishing two types of purinergic receptor. In: Straub R, Bolis L (eds) Cell Membr. Recept. Drugs Horm. A Multidiscip. Approach. Raven Press, New York, pp. 107–118
Abbracchio MP, Burnstock G (1994) Purinoceptors: are there families of P2X and P2Y purinoceptors? Pharmacol Ther 64:445–475
Ralevic V, Burnstock G (1998) Receptors for purines and pyrimidines. Pharmacol Rev 50:413–492
Burnstock G, Kennedy C (1985) Is there a basis for distinguishing two types of P2-purinoceptor? Gen Pharmacol 16:433–440
Burnstock G (2004) Cotransmission. Curr Opin Pharmacol 4:47–52. doi:10.1016/j.coph.2003.08.001
Pankratov Y, Lalo U, Krishtal O, Verkhratsky A (2002) Ionotropic P2X purinoreceptors mediate synaptic transmission in rat pyramidal neurones of layer II/III of somato-sensory cortex. J Physiol 542:529–536
Burnstock G (2014) Purinergic signalling: from discovery to current developments. Exp Physiol 99:16–34. doi:10.1113/expphysiol.2013.071951
Burnstock G (2006) Purinergic signalling. Br J Pharmacol 147(Suppl):S172–S181. doi:10.1038/sj.bjp.0706429
Inoue K (2007) P2 receptors and chronic pain. Purinergic Signal 3:135–144. doi:10.1007/s11302-006-9045-8
Inoue K (2006) ATP receptors of microglia involved in pain. Novartis Found Symp 276:263–272 discussion 273–81
Burnstock G, Krügel U, Abbracchio MP, Illes P (2011) Purinergic signalling: from normal behaviour to pathological brain function. Prog Neurobiol 95:229–274. doi:10.1016/j.pneurobio.2011.08.006
Rodríguez-Zayas AE, Torrado AI, Rosas OR et al (2011) Blockade of P2 nucleotide receptors after spinal cord injury reduced the gliotic response and spared tissue. J Mol Neurosci 46:167–176. doi:10.1007/s12031-011-9567-6
Franke H, Krügel U, Illes P (2006) P2 receptors and neuronal injury. Pflugers Arch 452:622–644. doi:10.1007/s00424-006-0071-8
Majumder P, Trujillo CA, Lopes CG et al (2007) New insights into purinergic receptor signaling in neuronal differentiation, neuroprotection, and brain disorders. Purinergic Signal 3:317–331. doi:10.1007/s11302-007-9074-y
Nagoshi N, Nakashima H, Fehlings MG (2015) Riluzole as a neuroprotective drug for spinal cord injury: from bench to bedside. Molecules 20:7775–7789. doi:10.3390/molecules20057775
Fehlings MG, Wilson JR, Frankowski RF et al (2012) Riluzole for the treatment of acute traumatic spinal cord injury: rationale for and design of the NACTN phase I clinical trial. J Neurosurg Spine 17:151–156. doi:10.3171/2012.4.AOSPINE1259
Wilson JR, Fehlings MG (2014) Riluzole for acute traumatic spinal cord injury: a promising neuroprotective treatment strategy. World Neurosurg 81:825–829. doi:10.1016/j.wneu.2013.01.001
Chow DSL, Teng Y, Toups EG et al (2012) Pharmacology of riluzole in acute spinal cord injury. J Neurosurg Spine 17:129–140. doi:10.3171/2012.5.AOSPINE12112
Grossman RG, Fehlings MG, Frankowski RF et al (2014) A prospective, multicenter, phase I matched-comparison group trial of safety, pharmacokinetics, and preliminary efficacy of riluzole in patients with traumatic spinal cord injury. J Neurotrauma 31:239–255. doi:10.1089/neu.2013.2969
Wells JEA, Hurlbert RJ, Fehlings MG, Yong VW (2003) Neuroprotection by minocycline facilitates significant recovery from spinal cord injury in mice. Brain 126:1628–1637. doi:10.1093/brain/awg178
Garrido-Mesa N, Zarzuelo A, Gálvez J (2013) Minocycline: far beyond an antibiotic. Br J Pharmacol 169:337–352. doi:10.1111/bph.12139
Tikka TM, Koistinaho JE (2001) Minocycline provides neuroprotection against N-methyl-D-aspartate neurotoxicity by inhibiting microglia. J Immunol 166:7527–7533
Nagoshi N, Fehlings MG (2015) Investigational drugs for the treatment of spinal cord injury: review of preclinical studies and evaluation of clinical trials from phase I to II. Expert Opin Investig Drugs 24:645–658. doi:10.1517/13543784.2015.1009629
Peng W, Cotrina ML, Han X et al (2009) Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injury. Proc Natl Acad Sci U S A 106:12489–12493. doi:10.1073/pnas.0902531106
Marcillo A, Frydel B, Bramlett HM, Dietrich WD (2012) A reassessment of P2X7 receptor inhibition as a neuroprotective strategy in rat models of contusion injury. Exp Neurol 233:687–692. doi:10.1016/j.expneurol.2011.06.008
Pojoga LH, Haghiac ML, Moose JE, Hilderman RH (2004) Determination of ATP impurity in adenine dinucleotides. Nucleosides Nucleotides Nucleic Acids 23:581–598. doi:10.1081/NCN-120030716
Pojoga LH, Haghiac M, Hilderman RH (2002) Inhibition by adenine dinucleotides of ATP-induced prostacyclin release by bovine aortic endothelial cells. Biochem Pharmacol 64:405–412
Wildman SS, Brown SG, King BF, Burnstock G (1999) Selectivity of diadenosine polyphosphates for rat P2X receptor subunits. Eur J Pharmacol 367:119–123
Chang H, Yanachkov IB, Michelson AD et al (2010) Agonist and antagonist effects of diadenosine tetraphosphate, a platelet dense granule constituent, on platelet P2Y1, P2Y12 and P2X1 receptors. Thromb Res 125:159–165. doi:10.1016/j.thromres.2009.11.006
Conant AR, Fisher MJ, McLennan AG, Simpson AW (2000) Diadenosine polyphosphates are largely ineffective as agonists at natively expressed P2Y(1) and P2Y(2) receptors on cultured human saphenous vein endothelial cells. J Vasc Res 37:548–555
Crooke A, Mediero A, Guzmán-Aránguez A, Pintor J (2009) Silencing of P2Y2 receptor delays Ap4A-corneal re-epithelialization process. Mol Vis 15:1169–1178
Pintor J, King BF, Miras-Portugal MT, Burnstock G (1996) Selectivity and activity of adenine dinucleotides at recombinant P2X2 and P2Y1 purinoceptors. Br J Pharmacol 119:1006–1012
Lazarowski ER, Watt WC, Stutts MJ et al (1995) Pharmacological selectivity of the cloned human P2U-purinoceptor: potent activation by diadenosine tetraphosphate. Br J Pharmacol 116:1619–1627
Schachter JB, Li Q, Boyer JL et al (1996) Second messenger cascade specificity and pharmacological selectivity of the human P2Y1-purinoceptor. Br J Pharmacol 118:167–173
Communi D, Motte S, Boeynaems JM, Pirotton S (1996) Pharmacological characterization of the human P2Y4 receptor. Eur J Pharmacol 317:383–389
Marteau F, Le Poul E, Communi D et al (2003) Pharmacological characterization of the human P2Y13 receptor. Mol Pharmacol 64:104–112. doi:10.1124/mol.64.1.104
Zhang H (2008) P2,P3-[18F] Monofluoromethylene diadenosine-5′,5″’-P1,P4-tetraphosphate. In: Mol. Imaging Contrast Agent Database (MICAD). Natl. Cent. Biotechnol. Information, NLM, NIH, Bethesda, MD. http://www.ncbi.nlm.nih.gov/books/NBK22992/pdf/Bookshelf_NBK22992.pdf.
Pintor J, Miras-Portugal MT (1995) A novel receptor for diadenosine polyphosphates coupled to calcium increase in rat midbrain synaptosomes. Br J Pharmacol 115:895–902
Zamecnik PC, Stephenson ML, Janeway CM, Randerath K (1966) Enzymatic synthesis of diadenosine tetraphosphate and diadenosine triphosphate with a purified lysyl-sRNA synthetase. Biochem Biophys Res Commun 24:91–97
Miras-Portugal MT, Gualix J, Pintor J (1998) The neurotransmitter role of diadenosine polyphosphates. FEBS Lett 430:78–82
Rodriguez del Castillo A, Torres M, Delicado EG, Miras-Portugal MT (1988) Subcellular distribution studies of diadenosine polyphosphates—Ap4A and Ap5A—in bovine adrenal medulla: presence in chromaffin granules. J Neurochem 51:1696–1703
Pintor J, Díaz-Rey MA, Torres M, Miras-Portugal MT (1992) Presence of diadenosine polyphosphates—Ap4A and Ap5A—in rat brain synaptic terminals. Ca2+ dependent release evoked by 4-aminopyridine and veratridine. Neurosci Lett 136:141–144
Pintor J, Rotllán P, Torres M, Miras-Portugal MT (1992) Characterization and quantification of diadenosine hexaphosphate in chromaffin cells: granular storage and secretagogue-induced release. Anal Biochem 200:296–300
Carracedo G, Peral A, Pintor J (2010) Diadenosine polyphosphates in tears of Sjogren syndrome patients. Invest Ophthalmol Vis Sci 51:5452–5459. doi:10.1167/iovs.09-5088
Pintor J (2003) Presence of diadenosine polyphosphates in the aqueous humor: their effect on intraocular pressure. J Pharmacol Exp Ther 304:342–348. doi:10.1124/jpet.102.041368
Pintor J, Bautista A, Carracedo G, Peral A (2004) UTP and diadenosine tetraphosphate accelerate wound healing in the rabbit cornea. Ophthalmic Physiol Opt 24:186–193. doi:10.1111/j.1475-1313.2004.00182.x
Hoyle CHV, Pintor JJ (2010) Diadenosine tetraphosphate protects sympathetic terminals from 6-hydroxydopamine-induced degeneration in the eye. Acta Physiol 199:205–210. doi:10.1111/j.1748-1716.2010.02089.x
Wang Y, Chang C-F, Morales M et al (2003) Diadenosine tetraphosphate protects against injuries induced by ischemia and 6-hydroxydopamine in rat brain. J Neurosci 23:7958–7965
Harvey BK, Chou J, Shen H et al (2009) Diadenosine tetraphosphate reduces toxicity caused by high-dose methamphetamine administration. Neurotoxicology 30:436–444. doi:10.1016/j.neuro.2009.02.003
Grynkiewicz G, Poenie M, Tsien RY (1985) A new generation of Ca2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440–3450
Negulescu PA, Machen TE (1990) Intracellular ion activities and membrane transport in parietal cells measured with fluorescent dyes. Methods Enzymol 192:38–81
Gürer B, Kahveci R, Gökçe EC et al (2015) Evaluation of topical application and systemic administration of rosuvastatin in preventing epidural fibrosis in rats. Spine J 15:522–529. doi:10.1016/j.spinee.2014.10.018
Louw AM, Kolar MK, Novikova LN et al (2016) Chitosan polyplex mediated delivery of miRNA-124 reduces activation of microglial cells in vitro and in rat models of spinal cord injury. Nanomedicine 12:643–653. doi:10.1016/j.nano.2015.10.011
Basso DM, Fisher LC, Anderson AJ et al (2006) Basso mouse scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains. J Neurotrauma 23:635–659. doi:10.1089/neu.2006.23.635
Hamm RJ, Pike BR, O’Dell DM et al (1994) The rotarod test: an evaluation of its effectiveness in assessing motor deficits following traumatic brain injury. J Neurotrauma 11:187–196
Rabchevsky AG, Fugaccia I, Sullivan PG, Scheff SW (2001) Cyclosporin a treatment following spinal cord injury to the rat: behavioral effects and stereological assessment of tissue sparing. J Neurotrauma 18:513–522. doi:10.1089/089771501300227314
Liverman BM, Altevogt CT, Joy JE, Johnson RT (2005) Spinal cord injury: progress, promise, and priorities. The National Academies Press, Washington D.C
Onose G, Anghelescu A, Muresanu DF et al (2009) A review of published reports on neuroprotection in spinal cord injury. Spinal cord Off J Int Med Soc Paraplegia 47:716–726. doi:10.1038/sc.2009.52
Silva NA, Sousa N, Reis RL, Salgado AJ (2014) From basics to clinical: a comprehensive review on spinal cord injury. Prog Neurobiol 114:25–57. doi:10.1016/j.pneurobio.2013.11.002
Hall ED, Springer JE (2004) Neuroprotection and acute spinal cord injury: a reappraisal. NeuroRx 1:80–100. doi:10.1602/neurorx.1.1.80
Gómez-Villafuertes R, del Puerto A, Díaz-Hernández M et al (2009) Ca2+/calmodulin-dependent kinase II signalling cascade mediates P2X7 receptor-dependent inhibition of neuritogenesis in neuroblastoma cells. FEBS J 276:5307–5325. doi:10.1111/j.1742-4658.2009.07228.x
León-Otegui M, Gómez-Villafuertes R, Díaz-Hernández JI et al (2011) Opposite effects of P2X7 and P2Y2 nucleotide receptors on α-secretase-dependent APP processing in neuro-2a cells. FEBS Lett 585:2255–2262. doi:10.1016/j.febslet.2011.05.048
Ennion SJ, Evans RJ (2001) Agonist-stimulated internalisation of the ligand-gated ion channel P2X(1) in rat vas deferens. FEBS Lett 489:154–158
Lalo U, Allsopp RC, Mahaut-Smith MP, Evans RJ (2010) P2X1 receptor mobility and trafficking; regulation by receptor insertion and activation. J Neurochem 113:1177–1187. doi:10.1111/j.1471-4159.2010.06730.x
Dutton JL, Poronnik P, Li GH et al (2000) P2X(1) receptor membrane redistribution and down-regulation visualized by using receptor-coupled green fluorescent protein chimeras. Neuropharmacology 39:2054–2066
Li GH, Lee EM, Blair D et al (2000) The distribution of P2X receptor clusters on individual neurons in sympathetic ganglia and their redistribution on agonist activation. J Biol Chem 275:29107–29112. doi:10.1074/jbc.M910277199
Bobanovic LK, Royle SJ, Murrell-Lagnado RD (2002) P2X receptor trafficking in neurons is subunit specific. J Neurosci 22:4814–4824
Royle SJ, Bobanović LK, Murrell-Lagnado RD (2002) Identification of a non-canonical tyrosine-based endocytic motif in an ionotropic receptor. J Biol Chem 277:35378–35385. doi:10.1074/jbc.M204844200
Koenig JA, Edwardson JM (1997) Endocytosis and recycling of G protein-coupled receptors. Trends Pharmacol Sci 18:276–287
Koenig JA (2004) Assessment of receptor internalization and recycling. Methods Mol Biol 259:249–273. doi:10.1385/1-59259-754-8:249
Donnelly-Roberts DL, Namovic MT, Han P, Jarvis MF (2009) Mammalian P2X7 receptor pharmacology: comparison of recombinant mouse, rat and human P2X7 receptors. Br J Pharmacol 157:1203–1214. doi:10.1111/j.1476-5381.2009.00233.x
Haghiac M, Pojoga LH, Hilderman RH (2001) Studies on the effect of diadenlyated nucleotides on calcium mobilization and prostacyclin synthesis in bovine aortic endothelial cells. Cell Signal 13:145–150
Gómez-Villafuertes R, Gualix J, Miras-Portugal MT, Pintor J (2000) Adenosine 5′-tetraphosphate (Ap(4)), a new agonist on rat midbrain synaptic terminal P2 receptors. Neuropharmacology 39:2381–2390
Miras-Portugal MT, Gualix J, Mateo J et al (1999) Diadenosine polyphosphates, extracellular function and catabolism. Prog Brain Res 120:397–409
Miras-Portugal MT, Pintor J, Gualix J (2003) Ca2+ signalling in brain synaptosomes activated by dinucleotides. J Membr Biol 194:1–10. doi:10.1007/s00232-003-2024-x
Varshavsky A (1983) Diadenosine 5′, 5′′′-P1, P4-tetraphosphate: a pleiotropically acting alarmone? Cell 34:711–712. doi:10.1016/0092-8674(83)90526-3
Ribeiro FF, Xapelli S, Miranda-Lourenço C et al (2015) Purine nucleosides in neuroregeneration and neuroprotection. Neuropharmacology. doi:10.1016/j.neuropharm.2015.11.006
Reigada D, Nieto-Díaz M, Navarro-Ruiz R et al (2015) Acute administration of ucf-101 ameliorates the locomotor impairments induced by a traumatic spinal cord injury. Neuroscience 300:404–417. doi:10.1016/j.neuroscience.2015.05.036
Basso DM (2004) Behavioral testing after spinal cord injury: congruities, complexities, and controversies. J Neurotrauma 21:395–404. doi:10.1089/089771504323004548
Flynn JR, Graham BA, Galea MP, Callister RJ (2011) The role of propriospinal interneurons in recovery from spinal cord injury. Neuropharmacology 60:809–822. doi:10.1016/j.neuropharm.2011.01.016
Bareyre FM, Kerschensteiner M, Raineteau O et al (2004) The injured spinal cord spontaneously forms a new intraspinal circuit in adult rats. Nat Neurosci 7:269–277. doi:10.1038/nn1195
Miras-Portugal MT, Gomez-Villafuertes R, Gualix J et al (2015) Nucleotides in neuroregeneration and neuroprotection. Neuropharmacology. doi:10.1016/j.neuropharm.2015.09.002
Gómez-Villafuertes R, Rodríguez-Jiménez FJ, Alastrue-Agudo A et al (2015) Purinergic receptors in spinal cord-derived ependymal stem/progenitor cells and their potential role in cell-based therapy for spinal cord injury. Cell Transplant 24:1493–1509. doi:10.3727/096368914X682828
Khakh BS, North RA (2006) P2X receptors as cell-surface ATP sensors in health and disease. Nature 442:527–532. doi:10.1038/nature04886
Gourine AV, Dale N, Llaudet E et al (2007) Release of ATP in the central nervous system during systemic inflammation: real-time measurement in the hypothalamus of conscious rabbits. J Physiol 585:305–316. doi:10.1113/jphysiol.2007.143933
Khakh BS, Henderson G (1998) ATP receptor-mediated enhancement of fast excitatory neurotransmitter release in the brain. Mol Pharmacol 54:372–378
Jeremic A, Jeftinija K, Stevanovic J et al (2001) ATP stimulates calcium-dependent glutamate release from cultured astrocytes. J Neurochem 77:664–675
Arthur DB, Georgi S, Akassoglou K, Insel PA (2006) Inhibition of apoptosis by P2Y2 receptor activation: novel pathways for neuronal survival. J Neurosci 26:3798–3804. doi:10.1523/JNEUROSCI.5338-05.2006
Wildman SS, Unwin RJ, King BF (2003) Extended pharmacological profiles of rat P2Y2 and rat P2Y4 receptors and their sensitivity to extracellular H+ and Zn2+ ions. Br J Pharmacol 140:1177–1186. doi:10.1038/sj.bjp.0705544
Loma P, Guzman-Aranguez A, Pérez de Lara MJ, Pintor J (2015) Diadenosine tetraphosphate induces tight junction disassembly thus increasing corneal epithelial permeability. Br J Pharmacol 172:1045–1058. doi:10.1111/bph.12972
Acknowledgments
We would like to thank Dr. Claire H. Mitchell and Dr. Jesús Pintor for their helpful comments and their kind criticism in the preparation of this manuscript. This work was supported by Fundación para la Investigación Sanitaria de Castilla la Mancha (FISCAM). PI-2010/19. We thank the technical and logistic support to the Fundación del Hospital Nacional de Parapléjicos para la Investigación y la Integración (FUHNPAIIN) and the microscopy and cytometry facilities of the Experimental Neurology Unit, Hospital Nacional de Parapléjicos, Toledo, Spain.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Reigada, D., Navarro-Ruiz, R.M., Caballero-López, M.J. et al. Diadenosine tetraphosphate (Ap4A) inhibits ATP-induced excitotoxicity: a neuroprotective strategy for traumatic spinal cord injury treatment. Purinergic Signalling 13, 75–87 (2017). https://doi.org/10.1007/s11302-016-9541-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11302-016-9541-4